|
1
|
Lee J, Park S, Kim SH, Kim J, Ryu J, Park
HS, Kim SI and Park BW: Characteristics and survival of breast
cancer patients with multiple synchronous or metachronous primary
cancers. Yonsei Med J. 56:1213–1220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Softic N: Acute myeloblastic leukemia in
an 84-year-old woman, associated with a breast cancer and a mixed
parotid tumor without metastasis. Nouv Rev Fr Hematol. 4:458–460.
1964.(In French). PubMed/NCBI
|
|
3
|
Carey RW, Holland JF, Sheehe PR and Graham
S: Association of cancer of the breast and acute myelocytic
leukemia. Cancer. 20:1080–1088. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosner F, Carey RW and Zarrabi MH: Breast
cancer and acute leukemia: Report of 24 cases and review of the
literature. Am J Hematol. 4:151–172. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ershler WB, Robins HI, Davis HL, Hafez GR,
Meisner LF, Dahlberg S and Arndt C: Emergence of acute
non-lymphocytic leukemia in breast cancer patients. Am J Med Sci.
284:23–31. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mishra PP, Mahapatra M, Choudhry VP,
Saxena R, Pati H, Dixit A, Anupama R, Bhattacharya J, Chatterjee T
and Dutta P: Synchronous occurrence of breast carcinoma and acute
myeloid leukemia: Case report and review of the literature. Ann
Hematol. 83:541–543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu G, Mallik DK, Yang W, Hou Y, Cheng Z,
Chen P, Zhu W, Wang H, Shen L, Zhang H and Yang Z: Appropriate
clinical strategies for breast cancer coexisting with acute myeloid
leukemia in the genomic-molecular era: A case report. Breast Care
(Basel). 11:145–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ballotta L, Trisolini SM, Iori AP, Rocca
UL, Micozzi A, Gentile G, De Giacomo T, Guarini A, Foà R and Capria
S: A rare case of coexisting breast cancer and refractory acute
myeloid leukemia. Case Rep Hematol. 2020:88931852020.PubMed/NCBI
|
|
9
|
Litzow MR: The therapy of relapsed acute
leukaemia in adults. Blood Rev. 18:39–63. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
D'Aguanno S and Del Bufalo D: Inhibition
of anti-apoptotic Bcl-2 proteins in preclinical and clinical
studies: Current overview in cancer. Cells. 9:12872020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maji S, Panda S, Samal SK, Shriwas O, Rath
R, Pellecchia M, Emdad L, Das SK, Fisher PB and Dash R: Bcl-2
antiapoptotic family proteins and chemoresistance in cancer. Adv
Cancer Res. 137:37–75. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roberts AW, Wei AH and Huang DCS: BCL-2
and MCL-1 inhibitors for hematologic malignancies. Blood.
138:1120–1136. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lagadinou ED, Sach A, Callahan K, Rossi
RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer
KM, et al: BCL-2 inhibition targets oxidative phosphorylation and
selectively eradicates quiescent human leukemia stem cells. Cell
Stem Cell. 12:329–341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alhoshani A, Alatawi FO, Al-Anaz FE,
Attafi IM, Zeidan A, Agouni A, El Gamal HM, Shamoon LS, Khalaf S
and Korashy HM: BCL-2 inhibivtor venetoclax induces
autophagy-associated cell death, cell cycle arrest, and apoptosis
in human breast cancer cells. Onco Targets Ther. 13:13357–13370.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Caroline AS, Vaine SR and Kevin WE: NIH
Image to ImageJ: 25 Years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar
|
|
17
|
Oberauner-Wappis L, Loibner M, Viertler C,
Groelz D, Wyrich R and Zatlouka K: Protocol for HER2 FISH
determination on PAXgene-fixed and paraffin-embedded tissue in
breast cancer. Int J Exp Pathol. 97:202–206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gobbini E, Ezzalfani M, Dieras V, Bachelot
T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A,
Dalenc F, et al: Time trends of overall survival among metastatic
breast cancer patients in the real-life ESME cohort. Eur J Cancer.
96:17–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hortbagyi GN, Stemmer SM, Burris HA, Yap
YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell
KL, Winer EP, et al: Updated results from MONALEESA-2, a phase III
trial of first-line ribociclib plus letrozole versus placebo plus
letrozole in hormone receptor-positive, HER2-negative advanced
breast cancer. Ann Oncol. 29:1541–1547. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Di Leo A, Jerusalem G, Petruzelka L,
Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL,
Smirnova I, Lichinitser MR, et al: Results of the CONFIRM phase III
trial comparing fulvestrant 250 mg with fulvestrant 500 mg in
postmenopausal women with estrogen receptor-positive advanced
breast cancer. J Clin Oncol. 28:4594–4600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reinert T and Barrios CH: Optimal
management of hormone receptor positive metastatic breast cancer in
2016. Ther Adv Med Oncol. 7:304–320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rozeboom B, Dey N and De P: ER+ metastatic
breast cancer: Past, present, and a prescription for an
apoptosis-targeted future. Am J Cancer Res. 9:2821–2831.
2019.PubMed/NCBI
|
|
24
|
Piezzo M, Cocco S, Caputo R, Cianniello D,
Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M and
De Laurentiis M: Targeting cell cycle in breast cancer: CDK4/6
inhibitors. Int J Mol Sci. 21:64792020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moreau-Bachelard C, Robert M, Gourmelon C,
Bourbouloux E, Patsouris A, Frenel JS and Campone M: Evaluating
everolimus for the treatment of breast cancer. Expert Opin
Pharmacother. 24:1105–1111. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
André F, Ciruelos EM, Juric D, Loibl S,
Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, et
al: Alpelisib plus fulvestrant for PIK3CA-mutated, hormone
receptor-positive, human epidermal growth factor
receptor-2-negative advanced breast cancer: Final overall survival
results from SOLAR 1. Ann Oncol. 32:208–217. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lok SW, Whittle JR, Vaillant F, The CE, Lo
LL, Policheni An, Bergin ART, Desai J, Ftouni S and Gandolfo LC: A
phase Ib dose-escalation and expansion study of the BCL2 inhibitor
venetoclax combined with tamoxifen in ER and BCL2-positive
metastatic breast cancer. Cancer Discov. 9:354–369. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tiribelli M, Michelutti A, Cavallin M, Di
Giusto S, Simeone E, Fanin R and Damiani D: BCL-2 expression in AML
patients over 65 years: Impact on outcomes across different
therapeutic strategies. J Clin Med. 10:50962021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Konopleva M, Pollyea DA, Potluri J, Chyla
B, Hogdal L, Busman T, Mckeegan E, Salem AH, Zhu M, Ricker JL, et
al: Efficacy and biological correlates of response in a phase II
study of venetoclax monotherapy in patients with acute myelogenous
leukemia. Cancer Discov. 6:1106–1117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bogenberger JM, Kornblau SM, Pierceall WE,
Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary
A, et al: BCL-2 family proteins as 5-Azacytidine-sensitizing
targets and determinants of response in myeloid malignancies.
Leukemia. 28:1657–1665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei AH, Strickland SA Jr, Hou JZ, Fiedler
W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, et al:
Venetoclax combined with low-dose cytarabine for previously
untreated patients with acute myeloid leukemia: Results from a
phase Ib/II study. J Clin Oncol. 37:1277–1284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
DiNardo CD, Pratz K, Pullarkat V, Jonas
BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH,
Kantarjian HM, et al: Venetoclax combined with decitabine or
azacitidine in treatment-naive, elderly patients with acute myeloid
leukemia. Blood. 133:7–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Röllig C, Bornhäuser M, Thiede C, Taube F,
Kramer M, Mohr B, Aulitzky W, Bodenstein H, Tischler HJ, Stuhlmann
R, et al: Long-term prognosis of acute myeloid leukemia according
to the new genetic risk classification of the European LeukemiaNet
recommendations: Evaluation of the proposed reporting system. J
Clin Oncol. 29:2758–2765. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mrózek K: Cytogenetic, molecular genetic,
and clinical characteristics of acute myeloid leukemia with a
complex karyotype. Semin Oncol. 35:365–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Breems DA, Van Putten WLJ, De Greef GE,
Van Zelderen-Bhola SL, Gerssen-schoorl KB, Mellink CH, Nieuwint A,
Jotterand M, Hagemeijer A, Beverloo HB and Löwenberg B: Monosomal
karyotype in acute myeloid leukemia: A better indicator of poor
prognosis than a complex karyotype. J Clin Oncol. 26:4791–4797.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wierzbowska A, Wawrzyniak E,
Siemieniuk-Rys M, Kotkowska A, Pluta A, Golos A, Robak T,
Szarawarska M, Jaskowiec A, Duszenko E, et al: Concomitance of
monosomal karyotype with at least 5 chromosomal abnormalities is
associated with dismal treatment outcome of AML patients with
complex karyotype-retrospective analysis of Polish adult leukemia
group (PALG). Leuk Lymphoma. 58:889–897. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Estey EH: Acute myeloid leukemia: 2019
Update on risk-stratification and management. Am J Hematol.
93:1267–1291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Daneshbod Y, Kohan L, Taghadosi V,
Weinberg OK and Arber DA: Prognostic significance of complex
karyotypes in acute myeloid leukemia. Curr Treat Options Oncol.
20:152019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alcon C, Gómez Tejeda Zañudo J, Albert R,
Wagle N, Scaltriti M, Letai A, Samitier J and Montero J: ER+ breast
cancer strongly depends on MCL-1 and BCL-xL anti-apoptotic
proteins. Cells. 10:16592021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vaillant F, Merino D, Lee L, Breslin K,
Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ,
et al: Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen
receptor-positive breast cancer. Cancer Cell. 24:120–129. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lindeman GJ, Fernando TM, Bowen R, Jezak
KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, et
al: VERONICA: Randomized phase II study of fulvestrant and
venetoclax in ER-positive metastatic breast cancer post-CDK4/6
inhibitors-efficacy, safety, and biomarker results. Clin Cancer
Res. 28:3256–3267. 2022. View Article : Google Scholar : PubMed/NCBI
|
